Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$2.93 USD
+0.13 (4.64%)
Updated Jun 10, 2024 03:43 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Brokerage Reports
Esperion Therapeutics, Inc. [ESPR]
Reports for Purchase
Showing records 1 - 20 ( 155 total )
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
1Q24 Results; U.S. Label Expansions Show Initial Signs of Increased Sales Traction; Potential European Approval in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA U.S. Label Expansion For CV Risk Reduction All Set; Look For EMA Approval in 2Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA Ready, Set, Go for Label Expansions; March 31 PDUFA; Potential EMA Approval in 2Q24; Target to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Litigation Out, Cash In; Focus Solely On Timely E.U. Commercialization
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J